In a clinical trial, adolescents who had received a booster dose of reduced dose diphtheria–
tetanus-5-component acellular pertussis vaccine (Adacel®, Tdap) 5 years earlier maintained …

Pertussis vaccination policy varies across Europe, not only in the type of vaccine—whole
cell (wP) vs. acellular (aP1/2/3/5)—but also in the schedule and recommendation for …

Background. From 2010 to 2012, reported pertussis incidence in Vermont increased from
2.9 to 103 cases per 100,000 persons. A number of factors could be responsible for the …

Background: In clinical trials, diphtheria, tetanus and acellular pertussis vaccines have been
shown to be less reactogenic than whole-cell combination vaccines. Aim: To evaluate …

BACKGROUND: During the 1990s, the United States switched from combined diphtheria,
tetanus toxoids, whole-cell pertussis (DTwP) vaccines to combined acellular pertussis …

OBJECTIVE: Recent universal vaccination efforts among children in the United States have
markedly changed hospitalization patterns for many vaccine-preventable diseases. Infants …

Background In accordance with its mandate to provide guidance to Member States on health
policy matters, WHO issues a series of regularly updated position papers on vaccines and …

In order to impede the increase in pertussis incidence in the adolescent group, a school-
leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden …

The Advisory Committee on Immunization Practices recommends administering diphtheria,
tetanus and acellular pertussis (DTaP) vaccines to children at 2, 4, 6, 15–18 months, and 4 …

Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to
randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool …